Robert S. Ohgami MD, PhD
An MD, PhD graduate of Harvard University, Robert Ohgami is an Assistant Professor in the Department of Pathology at Stanford University. A hematopathologist and research investigator, he has authored dozens of primary literature publications, textbooks and chapters, and is a reviewer and editor for major journals including the Atlas of Genetics and Cytogenetics in Oncology and Haematology and the Journal of Molecular Diagnostics. Notable accolades include the Berard-Dorfman Founders Award from the Society for Hematopathology, teaching awards from Stanford University, and several research awards from the American Society of Hematology. His love of diagnostic hematopathology and teaching also drives his active translational research lab where he investigates the pathogenesis of hematolymphoid disorders.
Assistant Professor of Pathology
Unraveling the molecular mechanisms of disease in hematolymphoid neoplasms with particular emphasis on connecting genetic findings with classic morphologic, immunophenotypic and clinical manifestations.
2012-2015 Clinical Instructor in Hematopathology, Stanford University.
2015-present Assistant Professor of Pathology, Stanford University.
06/2000 A.B. summa cum laude, Molecular Biology, Princeton University.
06/08/2006 Ph.D. Harvard University.
06/05/2008 M.D. cum laude, Harvard Medical School.
06/05/2008 Health Sciences and Technology Program Graduate, MIT.
07/2008-06/2012 Resident, anatomic pathology, Stanford University Medical Center.
07/2010-06/2011 Fellow in hematopathology, Stanford University Medical Center.
07/2011-06/2012 Postdoctoral fellow, Stanford University Medical Center.
LICENSURE AND CERTIFICATION:
2008 Full California Medical License.
2012 Anatomic Pathology Board of Pathology Certification.
2012 Hematopathology Board of Pathology Certification.
HONORS AWARDS AND GRANTS:
1997 Pyka Prize for Excellence in Physics, Princeton University.
1998 President’s Award for Academic Excellence, Princeton University.
2000 summa cum laude, Princeton University.
2000 George Khoury ’65 Senior Prize for Academic Excellence, Princeton University.
2000 Phi Beta Kappa, Princeton University.
2000 Medical Scientist Training Program (MSTP) Scholarship, Harvard.
2005 American Society of Hematology Travel Award.
2005 International BioIron Society Travel Award.
2006 American Society of Hematology Trainee Research Award.
2008 National Scholars Honor Society Merit Award.
2008 cum laude, Harvard Medical School.
2008 American Society of Hematology Trainee Research Award.
2010 Scholar, Stanford Society of Physician Scholars.
2012 College of American Pathologists Scholars Research Fellowship
2013 Member, Stanford Cancer Institute.
2014 CP Junior Faculty Teaching Award, Stanford Department of Pathology.
2014 Foundation Medicine Research Grant.
2015 Investigator award, Agilent Technologies.
2016 Berard-Dorfman Founders Award, Society for Hematopathology
2016 AP Junior Faculty Teaching Award, Stanford Department of Pathology.
2015-2018 Principal Investigator; Agilent Technologies Research Award A molecular dissection of hematolymphoid neoplasms centered on next generation sequencing.
2014-2016 Principal Investigator; Foundation Medicine Research Grant Genomic profiling of rare hematolymphoid neoplasms.
2016-2017 Principal Investigator; Anneles Gramberg Award Molecular analysis of leukemias and lymphomas/p>
PEER REVIEWED PUBLICATIONS:
1. Ohgami RS, Campagna DR, Antiochos B, Wood EB, Sharp JJ, Barker JE, and Fleming MD. nm1054, a spontaneous, recessive, hypochromic, microcytic anemia mutation in the mouse. Blood. 2005; Nov 15;106(10):3625-31.
2. Ohgami RS, Campagna D, Greer E, Antiochos B, McDonald A, Chen J, Sharp J, Fujiwara Y, Barker J, and Fleming, MD. Identification of a ferrireductase required for efficient transferrindependent iron uptake in erythroid cells. Nature Genetics. 2005; 37:1264-1269. Commentary McKie AT. A ferrireductase fills the gap in the transferrin cycle. Nature Genetics 2005; 37:1159-1160.
3. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood. 2006; Aug 15; 108(4): 1388-94. Epub 2006, Apr 11.
4. Sendamarai A, Ohgami RS, Fleming MD, Lawrence C. Crystal Structure of the membrane proximal oxidoreductase domain of human Steap3, the major erythroid ferric reductase. Proc Natl Acad Sci USA. 2008 May 27;105(21):7410-5. Epub 2008 May 21.
5. Sangoi AR*, Ohgami RS*, Pai RK, Beck AH, McKenney JK, and Pai RK, PAX8 Expression Reliably Distinguishes Pancreatic Well-differentiated Neuroendocrine Tumors from Ileal and Pulmonary Well-Differentiated Neuroendocrine Tumors Modern Pathology 2010. Oct 1. [Epub ahead of print] *Equal contribution.
6. Younes SF, Beck AH, Ohgami RS, Lossos IS, Levy R, Warnke RA, Natkunam Y. The Efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B-cells in nodal and extranodal sites, including the bone marrow. American Journal of Clinical Pathology. 2011 May;135(5):697-708.
7. Ohgami RS, Ohgami JK, Pereira IT, Gitana G, Zehnder JL, Arber DA. Refining the diagnosis of T-cell large granular lymphocytic leukemia by combining distinct patterns of antigen expression with T-cell clonality studies. Leukemia, 2011 Sep;25(9):1439-43. doi: 10.1038/leu.2011.107.
8. Ohgami RS, Chun S, Ohgami JK, Zehnder J, Arber DA, Natkunam Y, Warnke R TdT+ Tlymphoblastic Populations are Increased in Castleman Disease, Castleman Disease in Association with Follicular Dendritic Cell Tumors, and Angioimmunoblastic T-cell Lymphoma. American Journal of Surgical Pathology. 2012 Nov; 36(11):1619-28.
9. Ohgami RS, Ma L, Ren L, Weinberg OK, Seetharam M, Gotlib J, Arber DA DNA methylation analysis of GSTM1 and ALOX12 in acute myeloid leukemia identifies prognostically significant groups. Brit J of Hem. Volume 159, Issue 2, pages 182–190, October 2012.
10. Ohgami RS, Zehnder J, Arber DA, Natkunam Y, Warnke R. Indolent T-lymphoblastic Proliferation (iT-LBP): A Review of Clinical and Pathologic Features and Distinction from Malignant T-lymphoblastic Lymphoma. Advances in Anatomic Pathology. 2013; 20 (3): 137-40.
11. Ohgami RS, Chisholm KM, Ma L, Arber DA. E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. American Journal of Clinical Pathology. 2014 May;141(5):656-64.
12. Ohgami RS, Atwater S, M Liedtke, Natkunam Y, Warnke R. Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression. American Journal of Surgical Pathology. 2014 Mar 10. [Epub ahead of print]
13. Ohgami RS, Zhao S, Natkunam Y. Large B-cell lymphomas poor in B-cells and rich in PD-1 positive T-cells can mimic a T-cell lymphoma. American Journal of Clinical Pathology. 2014 Aug;142(2):150-6. Editorial highlighting this article: 142:142-143 14. Weinberg OK, Ohgami RS, Ma L, Seo K, Ren L, Gotlib JR, Seetharam M, Cherry A, Arber DA. Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic and molecular findings. American Journal of Clinical Pathology. 2014 Aug;142(2):190-5.
15. Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA. Next generation sequencing of acute myeloid leukemia demonstrates the significance of TP53, U2AF1, ASXL1 and TET2 mutations. Mod Pathol. 2015 May;28(5):706-14. doi: 10.1038/modpathol.2014.160. Epub 2014 Nov 21.
16. Karnik T, Ozawa M, Lefterova M, Zehnder JL, Arber DA, Ohgami RS. The utility of IgM, CD21 and HGAL in the diagnosis of pediatric follicular lymphoma. Human Pathology. 2015. http://dx.doi.org/10.1016/j.humpath.2014.12.016
17. Chisholm KM, Gitana G, Merker JD, Gotlib JR, Lefterova M, Zehnder J, George TI, Arber DA, Ohgami RS. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol. 2015 Apr;143(4):527-34.
18. Kurtz DM, Green MR, Bratman SV, Scherer FP, Liu CL, Kunder C, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong K, Faham M, Corbelli KS, Miklos DB, Advani R, Levy R, Hicks RJ, Hertzberg MS, Ohgami RS, Gandhi MK, Diehn M, and Alizadeh AA Non-invasive monitoring of diffuse large B-cell lymphoma by immunoglobulin highthroughput sequencing. Blood 2015 Apr 17. pii: blood-2015-03-635169.
19. Johnson R, Weinberg OK, Cascio M, Mitton B, Dahl G, Silverman L, Cherry T, Arber DA, Ohgami RS. Cytogenetic variation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21q) – a multi-institutional series review. Am J Clin Pathol. 2015. Jul; 144(1):103-12.
20. Ohgami RS, Arber DA. The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. Int J Lab Hematol. 2015 May;37 Suppl 1:122-32. doi: 10.1111/ijlh.12367.
21. Weinberg OK, Rodig S, Pozdnyakova O, Li Ren, Arber DA, Ohgami RS. Surface Light Chain expression in Primary Mediastinal Large B-cell Lymphomas by Multiparameter Flow Cytometry. Am J Clin Pathol. 2015 Oct;144(4):635-41.
22. Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee C, Mah A, Zehnder A, Ohgami RS, Kulkarni S, Armstrong A, Gratzinger D, Rook A, Snyder M, Kim Y, Khavari P. Integrated Genomic Analysis of Cutaneous T-cell Lymphomas Identifies Recurrent Alterations in T-cell Signaling Pathways. Nat Genet. 2015 Aug 10. doi: 10.1038/ng.3370. [Epub ahead of print]
23. Hoffman J, Chisholm K, Cherry A, Chen J, Arber DA, Natkunam Y, Warnke R, Ohgami RS An analysis of of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. Human Pathology. 2016 Feb;48:9-17.
24. Fernandez-Pol S, Ma L, Ohgami RS, Arber DA. Significance of MDS-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol. 2016 Jun 3. doi: 10.1038/modpathol.2016.100.
25. Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print]
26. Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print]
27. Ozawa M*, Bhaduri A*, Link M, Luna-Fineman S, Ma L, Chisholm K, Zehnder J, Khavari P, Merker JD, Arber DA, Ohgami RS. A Study of the Mutational Landscape of Pediatric-type follicular lymphoma and Pediatric Nodal Marginal Zone Lymphoma. Modern Pathology. 2016 Jun 24. doi: 10.1038/modpathol.2016.102.
28. Chisholm KM, Ohgami RS, Tan B, Hasserjian RP, Weinberg OK. Primary Lymphoma of Bone in the Pediatric and Young Adult Population. Hum Pathol. 2016 Aug 20. pii: S0046- 8177(16)30182-4.
29. Alcasid M, Ma L, Gotlib JR, Arber DA, Ohgami RS. The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. Int J Lab Hematol 2016. Accepted.
PEER REVIEWED LETTERS:
30. Kohrt HE, Ohgami RS, Arber DA, Alizadeh A, Coutre S Diagnosing PNH in the era of FLAER. [e-letter]. Blood. 2011; Nov 9, 2011.
31. Ewalt MD, Abeynayake J, Waggoner JJ, Pinsky BA, Ohgami RS. Profound plasmacytosis in a patient with dengue fever. International Journal of Hematology. 2013 Nov;98(5):518-9. doi: 10.1007/s12185-013-1452-3. Epub 2013 Oct 11.
32. Ohgami RS, Ma L, Martinez B, Zehnder J, Arber DA. STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013 Apr 8. doi: 10.1038/leu.2013.104.
33. Ohgami RS, Ma L, Zehnder JL, Arber DA. STAT3 mutations are present in aggressive B-cell lymphomas with anaplastic morphology with a subset showing partial CD30 expression. Haematologica. 2014 May 16. pii: haematol.2013.101543. [Epub ahead of print].
34. Chalmers ZR, Ali SM, Ohgami RS, Vergilio J, Frampton GM, Ross JS, Yelensky R, Stephens PJ, Miller VA, Miles CR. Comprehensive Genomic Profiling identifies a Novel TNKS2- PDGFRA Fusion which defines a Myeloid Neoplasm with Eosinophilia that responded dramatically to Imatinib therapy. Blood Cancer Journal. 2015 5: e278; doi:10.1038/bcj.2014.95
35. Ohgami RS, Natkunam Y, Warnke R. Indolent T-lymphoblastic proliferation: a name with specific meaning. Hum Pathol. 2015 Aug 11. pii: S0046-8177(15)00289-0.
Ohgami RS, Ziai JM, Arber DA, Chapter 22. Disorders of the Spleen, in Hematopathology 2nd edition, edited by Hsi E. 2012
Ohgami RS, Arber DA. Challenges in consolidated reporting of hematopoietic neoplasms.
Surgical Pathology Clinics: Hematopoietic neoplasms: Controversies in Diagnosis and Classification, edited by George T. and Arber DA. 2013
Ohgami RS, Arber DA. Bone marrow therapy changes. In Hematopathology 2nd edition, edited by Jaffe E, Harris NL, Vardiman JW, Campo E, Arber DA. 2015.
Ohgami RS, Arber DA, Chapter 22. Disorders of the Spleen, in Hematopathology 3rd edition, edited by Hsi E. 2016
2016-present The Journal of Molecular Diagnostics
Ad Hoc Reviewer:
Blood; Modern Pathology; Haematologica; The Journal of Molecular Diagnostics; PLOS One; The American Journal of Pathology; The American Journal of Clinical Pathology; Histology and Histopathology; BMC Cancer; Archives of Pathology and Laboratory Medicine; Cytometry: Part B – Clinical Cytometry; International Journal of Laboratory Hematology; Apoptosis; Cancer Medicine; Journal of Hematopathology; Journal of Clinical Pathology; Current Medical Research and Opinion; Clinical Therapeutics; Clinical Medicine Insights: Oncology; Journal of Pathology and Translational Medicine
FORMAL TEACHING OF MEDICAL STUDENTS, RESIDENTS AND FELLOWS:
2003-2005 Teaching Assistant and Tutor. Chemistry and Biology of the Cell. Harvard Medical School. 50 hours/year. 20 students/year.
2006-2008 Medical student instructor/tutor. Harvard Medical School.
2011 Stanford pathology residency gross room conference instructor.
2011-present Stanford medical school hematology lab instructor.
2013-present Hematopathology Slide Session (Lymph node pathology). Four sessions per year.
2012-present LPCH Hematology/Oncology Series Lectures (Bone marrow pathology, Flow cytometry, The acute leukemias, Lymphomas). Five sessions per year.
2013-present Hematology-Oncology Clinical Didactic lecture (T and NK cell neoplasms, Molecular hematopathology, Myeloid neoplasms).
2013-present Hematopathology resident teaching: (Plasma cell neoplasms, Hodgkin lymphoma, Acute leukemia, Flow cytometry, the CBC, Approach to the diagnosis of myeloid neoplasms).
2016-present Stanford Medical Student Lectures (Ancillary testing in acute myeloid leukemia, acute myeloid leukemia)
2009-2011 Delegate, College of American Pathologists' Residents Forum.
2010-2012 Associate Program Director (Founding), Stanford Society of Physician Scholars.
2013-present Stanford CP Hematology Rotation Director
2013-2015 Society for Hematopathology Planning Committee Member, 2015 Stanford Workshop on Immune Deficiency and Dysregulation
2014-2016 Medical School Admissions Reviewer, Stanford Medical School
2014-2015 Pathology Residency Selection Committee, Stanford University
2016 Leadership Group, Junior AP Faculty Member
2015-present Clinical Competency Committee Chair, Hematopathology Fellowship
2013-present Member, College of American Pathologists (CAP) Biomarker Reporting Committee (CBRC) Hematopathology - Lymphoid panel